PDE5A and Cirrhosis: In the study of Brusilovskaya et al. (2020) [48], the long-acting PDE-5 inhibitor tadalafil and the sGC stimulator riociguat decreased portal pressure and intrahepatic vascular resistance and diminished the extent of fibrosis in BDL-induced cirrhosis.